

OSLO BIO UPDATE

A newsletter from Oslo Teknopol covering activities in the life science cluster in the Oslo region

IN THIS ISSUE

VIEWPOINT - Global Biosciences Gateway visionary and Hamner CEO Bill Greenlee on why Norway as a lead partnerp.2

BUSINESS NEWS - new appointments at Axis-Shield, Biotec Pharmacon and Clavis, Novo backs C10, HUNT links with Tissue Solutionsp.4

BIO PROFILE - who's who in the Norwegian showcase in Chicagop.6

MEDTECH - Sonitor makes RTLS waves in US, wireless sensor project reportsp.9

NEUROSCIENCE - Nansen Network to launch in May.....p.11

OSLO CANCER CLUSTER - ECCP initial programme announced, focus on "Oncology 2020"p.11

ONE TO WATCH - Vaccibody provide cancer vaccines shot in the armp.12

Photo: © City of Chicago / GRC



NORWEGIAN BIOTECH BLOSSOMING - RECORD ATTENDANCE AT BIO 2010

A year on from Atlanta and the Norwegian life science industry arrives in Chicago more buoyant than ever before. The success of companies such as Algeta and Clavis who featured in BioCentury's top stocks of 2009 has already been emulated by PCI Biotech whose Phase I results in head and neck cancer are truly stunning. Close behind are Lytix and DiaGenic.

Norway's BIO organiser for the last 10 years, Knut Larsen feels this could be the most exciting BIO yet: "When I started we were mainly diagnostics and devices focussed, but I am now delighted to see a broad range of companies from therapeutics to services represented."

For profiles of the exhibitors including newcomers Genetic Analysis, Isentio and Vaccibody see Bio Profile inside.

Photo: Hamner Institute



OSLO TO BE EUROPEAN PORTAL OF NEW GLOBAL BIOSCIENCES GATEWAY

BIO2010 will also see the formal announcement of the creation of a new Global Biosciences Gateway designed to accelerate translational oncology and bring new diagnostics and treatments to market faster. Oslo Cancer Cluster will form the European portal for this, with Hamner Institute representing the US, and Shanghai, Asia.

See Viewpoint inside by Dr. William Greenlee, President and CEO of The Hamner Institutes for Health Sciences.

WHAT THE GLOBAL BIOSCIENCES GATEWAY MEANS TO OSLO

By Dr. William Greenlee, President and CEO of The Hamner Institutes for Health Sciences

In June 2008, Genome Technology named both Oslo, Norway, and North Carolina, USA, among the 20 best places for biotechnology in the world. Collaboration between Oslo and North Carolina, as well as other top biotechnology hubs in the world, is not only strategically sound, but critically necessary.

To capture the power of new discoveries and technologies emerging from recent advances in molecular and cellular biology, it is necessary to bridge the gap between the various fields of basic biomedical, epidemiological and clinical cancer research. No single cancer institution in the world has the critical mass to deliver in all cancer areas. Institutions should collaborate to create a world-class integrated infrastructure with the goal of advancing cancer prevention, diagnosis and treatment.

As CEO of the Oslo Cancer Cluster, Bjarte Reve strongly supports the need for global collaboration. After signing a Memorandum of Understanding with The Hamner Institutes for Health Sciences in Research Triangle Park, North Carolina, Reve said, *"We passionately believe that this partnership with The Hamner Institutes will enable companies and comprehensive cancer centers to speed development of new cancer therapies through global partnerships. Over the last few years, we have already taken great strides in Europe to bring together such clusters, with concrete results, such as a Phase 1 network and joint EU-IMI submissions. This partnership with The Hamner is a logical next step to forge stronger links with the United States and also to complement our existing initiatives in China."*

WHAT THE HAMNER INSTITUTES AND OSLO SHARE IN COMMON

What The Hamner and Research Triangle Park share in common with Oslo is a rich fabric of cutting-edge biomedical research located in an area with a high concentration of life sciences organizations and industry. Like the Whitehead Institute and the Broad Institute of MIT and Harvard, The Hamner is an independent 501(c)(3) biomedical research institution, and its strategic location on a 56-acre campus within Research Triangle Park provides ready access to world class universities — Duke Uni-



Photo: Hamner Institute

The Global Sciences Gateway aims to accelerate translational medicine worldwide.



Bill Greenlee is a passionate believer in international cooperation.

versity, the University of North Carolina at Chapel Hill, and North Carolina State University — and their associated medical campuses, as well as one of the USA's leading schools of veterinary medicine.

As a global leader in environmental health sciences and now with a broadened platform in biomedicine, The Hamner has trained hundreds of postdoctoral fellows and published thousands of papers in scientific journals. It acts as a catalyst to facilitate life sciences technology development among North Carolina universities, while serving as a gateway to establish research collaborations with leading universities, the bio/pharmaceutical industry and government agencies in Asia and Europe.

The Hamner's recently announced European cancer network with Norway's Oslo Cancer Cluster joins a number of established connections, including the Hamner-China Biosciences Center, to create a multi-pronged Global Biosciences Gateway that provides a platform to address critical world-wide needs in biomedicine and therapeutic development.

THE GLOBAL BIOSCIENCES GATEWAY

The Hamner Institutes established a Global Biosciences Gateway on its campus to enable biopharmaceutical companies and comprehensive cancer centers to accelerate development of new cancer therapies. The collaboration will create an infrastructure in both North Carolina and Oslo to advance cancer therapeutics discovery and drug development. The Hamner network along with its partners in Europe and Asia provide access

to drug safety and regulatory experts that can address regulatory requirements from the FDA, the EMEA and eventually the Chinese State Food and Drug Administration.

Specific initiatives of The Hamner-Oslo collaboration will focus on translational research, business development, and training and education. The Hamner will provide access to its network of research collaborators, including three Comprehensive Cancer Centers located in North Carolina within 70 miles of each other and The Hamner. North Carolina is one of only 2 states in the United States with three Comprehensive Cancer Centers funded by the US National Cancer Institute.

Because the Oslo Cancer Cluster is a world leader in cancer research and technology development, The Hamner's partnership with Oslo is a key link in a shared Global Biosciences Gateway and strategy to accelerate the development of new cancer therapeutics worldwide. The ability we now have to identify and capture cutting-edge cancer research in the USA, Europe and China will not only benefit patients, but also will be an important driver for business and economic development in our respective countries.

I am confident that through global collaborative partnerships we will be successful in advancing more effective and safer therapies for cancer that will benefit the world's citizens. It is a great privilege to be a partner with the Oslo Cancer Cluster in this effort.

AFFITECH SIGNS STRATEGIC ALLIANCE WITH RUSSIAN BIOTECH PARTNER

In return for €23 million in fees and advanced royalties, Affitech has entered into an alliance with NauchTekh-Stroy Plus, a joint venture subsidiary of Pharmstandard, Russia's leading domestic pharmaceutical company to develop for commercialisation two Affitech antibodies for the Russian and CIS market, AT001 (also known as r84) is a novel, proprietary therapeutic antibody to vascular endothelial growth factor (VEGF), which is being developed as a potential competitor to bevacizumab (Avastin®) for the treatment of certain human cancers. AT008 is a novel, proprietary therapeutic antibody directed against CCR4, an important G-protein coupled receptor ("GPCR") on the surface of many cancer cells and cells of the immune system.

www.affitech.com

CLOVIS TO DEVELOP HENT1 COMPANION DIAGNOSTIC FOR CLAVIS

Clavis Pharma's US partner Clovis Oncology is to work with Ventana Medical Systems Inc. to develop a companion diagnostic to CP-4126 (also known as CO-101) for clinical and commercial use. The companion diagnostic is being developed to identify pancreatic cancer patients with low-level tumour expression of the human equilibrative nucleoside transporter 1 (hENT1) protein. Ultimately, the use of a hENT1 companion diagnostic will enable oncologists to identify patients who may show a significant benefit from treatment with Clavis Pharma's novel drug candidates.

www.clavispharma.com



Nordiag's Arrow instrument offers desktop DNA sample preparations.

NORDIAG'S ARROW READY TO SHOOT

Nordiag's share price rose as it announced that both the necessary clinical documentation for CE IVD labeling has been submitted and UL certification has been completed for its desktop Arrow automated DNA extraction instrument. This should open the way for use in routine diagnostic laboratories in addition to research laboratories in Europe. www.nordiag.com




Photo: Aker-Biomarine

Norway leads the way in developing marine oil supplements.

SUPERBA™ KRILL OIL READY FOR THE EUROPEAN MARKET

Aker BioMarine has been notified by the Finnish Food Safety Authority that its Omega 3-rich Superba™ Krill Oil is now approved as Novel Food in the European Union. Consequently, Superba™ Krill Oil can be sold in all countries within the European Union. Aker claims that harvesting krill is more environmentally friendly and sustainable than deriving marine oils from fish.

Read more at www.akerbiomarine.com

LIEN TAKES OVER AT BIOTEC PHARMACON

Former Axis-Shield CEO Svein Lien has been appointed new CEO of Biotec Pharmacon and has immediately pledged to help the company refocus in the wake of disappointing Phase III results for its SBG wound care lead compound. *"I am looking forward to this challenge"* says Lien *"I know the company very well from several years as a Board Member and have always been very confident about the technology platform and admired the highly skilled and talented organisation. We will need some more time to identify the root cause behind the disappointing Phase III results and to clarify the strategic route forward. Following that we will inform the market, most likely via a capital market day in Q2."*

www.biotec.no

HUNT SIGNS BIOMARKER DEAL WITH TISSUE SOLUTIONS

HUNT Biosciences, the commercial arm of the HUNT general population biobank, has signed a collaboration agreement with UK-based Tissue Solutions designed to increase use of HUNT samples for biomarker discovery and validation.

www.huntbiosciences.com

BOARD CHANGES AT AXIS-SHIELD

Along with Svein Lien, mentioned above, another of the main architects of Axis-Shield's continuing international success in the diagnostics arena, chairman Nigel Keen, has announced his retirement. He will be succeeded by another renowned industry figure, Dr John Brown who is currently Chairman of BTG plc and CXR Biosciences Ltd and a Non-Executive Director of Vectura Group plc. Also joining the board is Professor Wenche Rolfsen who is herself chairman of Aprea AB and Denator AB, as well as a director of Industrifonden, Artimplant AB, Biovitrum AB and Aker BioMarine ASA.

AXIS-SHIELD TO PARTNER ABBOTT IN DIABETES

In a further strengthening of their long-standing relationship, Axis-Shield is to develop and commercialise a haemoglobin (HbA1c) immunoassay for diabetes monitoring to run on Abbott's flagship ARCHITECT® high throughput analyser system.

www.axis-shield.com

ANTIBIOTICS START-UP SECURES USD 1.5 MILLION FUNDING

C10 Pharma, a Norwegian biopharmaceutical company focused on developing novel antibiotics, has completed its first financing round, raising USD 1.5 million. The investors in the Series A round are Novo Seed, acting as lead investor, and Sarsia Seed. The company aims to develop the new antibiotics desperately needed to combat the increasing threat drug-resistant 'super-bugs'. Bobby Soni, Principal at Novo Seeds, will join the board of C10 Pharma: "C10 Pharma is our first Norwegian investment and we believe that C10 Pharma's innovative technology has the potential to result in important new antibiotic drugs addressing this critical medical need." CEO of the new company is Thorfinn Ege.

FORMER UCB MAN TAKES HELM AT CLAVIS

Having secured one of the deals of 2009 with Clovis, Clavis has appointed Olav Hellebø as its new CEO. Mr Hellebø, joins from UCB Pharma to lead the Clavis as it embarks on a new phase of international clinical and commercial development.

www.clavispharma.com

PCI CONTINUE TO SHINE

Following the results from the Phase I/II Amphinex trials at UCH, PCI Biotech has engaged DnB NOR Markets and Fondsfinans ASA as financial advisors to look at funding options. Based on the company's current situation, a share issue is a probable alternative. However, no final decisions have been made on timing, size of share issue or share issue structure. The proceeds from a possible share issue would be used to complete a phase II study within Head and Neck cancer, and completion of pre-clinical evaluations and clinical Proof of Concept studies of up to three other cancer indications. www.pcibiotech.no

EVENT CALENDAR 2010

Meet representatives from the Oslo life science sector at the following events:

MAY

3 – 6 Scandinavia Pavilion at Bio International Convention 2010, Chicago, USA
www.bio2010.org

11 Partnership for Innovation: From Cancer Research to Cure, Oslo Week, Norway at World Expo 2010 Shanghai, China
www.expo2010.no

JUNE

26 – 29 EACR21: 21st meeting of the European Association for Cancer Research in Oslo, Norway
www.ecco-org.eu

SEPT

15 – 17 ECCP 2010, 2nd European Cancer Cluster Partnering, Oslo, Norway
www.eccp2010.com



Photo: © City of Chicago / GRC

Norway will focus strongly on life sciences during 2010, both in Chicago at BIO and WorldExpo in Shanghai.

NORWEGIAN COMPANIES AT BIO2010

From innovative diagnostics to breakthrough therapeutics to life science tools and software, the Norwegian stand at BIO will present a wide spectrum of interest to visitors. Many are linked to oncology and members of the Oslo Cancer Cluster, which aims to provide an environment conducive to translational research - ie bringing products and services faster from bench-top to patients.

PCI Biotech will be giving updates on their ongoing Phase I trials for head and neck cancers in UCH. When activated by a laser their proprietary photosensitizer Amphinex enables the endosomal release of a cytotoxic agent, in this case bleomycin, into tumour cells. The results have been little short of amazing - inoperable tumours have completely disappeared within a matter of hours. CEO Per Walday will be looking for partners to apply the technology for delivery of other molecules.

Photocure is a world leader in photodynamic therapy and has already successfully licenced FDA-approved Hexvix for detecting bladder cancer to GE Healthcare. The company is currently evaluating its patented photodynamic technology for several diseases such as acne, pre-malignant cervix lesions/HPV-infections, colon cancer and for the cosmetic market of skin rejuvenation. Business Development Director Kjetil Widerberg will be looking for partners in these areas.

Lytix are another upcoming biopharma with two of their synthetic lytic peptides going into phase 1 - Oncopore for cancer and Lytixar for drug-resistant microbial and bacterial infections. The company is also involved in a trial using Oncopore in combination Kaelin-Gambetti GV1001, a telomerase peptide vaccine. Business Development Manager Anders Fugelli will be looking for licensing partners for other indications.

DiaGenic now have two of their blood-based early diagnostic tests CE marked. BCtect offers early detection based on a gene expression pattern recognition for breast cancer, while ADtect promises the same for Alzheimer's Disease. A third test for Parkinson's is under development. DiaGenic is also looking to target the clinical trials market, where it already is working on an MCI test for Merz Pharma. Marketing Director Dag Christensen is the key contact at BIO.

HUNT Biosciences are promoting the use of one of Norway's great healthcare assets, its general population based biobanks, for biomarker discovery and validation. Just one of the many benefits from this unique resource is that data and samples are available for individuals prior to them developing diseases. HUNT is also organising a breakout session during BIO with participants from Kaiser Permanente, IBM and Merck. CEO Per Foss is the main contact.

Biomolex continues a Norwegian tradition for biomedical instrumentation innovation with the Biomolex 700, a real time digital imager for autoradiographic recording of Kinase arrays and tissue sections. Compared to traditional film and phosphorus screen-based detection systems, Biomolex technology offers a range of advantages including real time detection through single event counting, energy registration, signal linearity over 5 log, increased sensitivity and improved image resolution. John Erik Stacy is looking for distributors at BIO.

Balter Medical has developed a handheld device for non invasive real time optical biopsy and diagnosis of Melanoma. Proof of Performance Clinical Trials have been concluded at Haugland Hospital Bergen Norway and continue at Mayo Clinic Arizona USA and at Norwich & Norfolk Hospital UK. Additional sites in USA and EU will come on line in the second half of 2010. CEO Richard Godfrey will be looking for partners to marketing the CE marked device in the EU in 2012 and after a PMA is filed with FDA in 2013.

BerGenBio offer RNAi technology for drug target validation and therapeutic development. A year on from their launch at BIO2009 and they have made major progress by signing multi year CRO contracts with big pharma, agri chemical and smaller drug discovery companies. Also a drug development collaboration with leading Asian drug development company. Most recently funding has been secured for development of novel cancer targets and associated therapeutics. CEO Richard Godfrey will be present to explain more.

iSentio has developed the online RipSeq application for hospitals and laboratories to rapidly identify mixed bacterial samples instead of having to wait for culturing. Using broad-range PCR targeting the 16S rRNA gene and DNA sequencing (Direct 16S rDNA sequencing) gives the possibility to identify bacteria that died during transportation or as a consequence of antibiotic treatment, and to uncover bacteria with special growth requirements. CEO Bjarte Karlsen is attending BIO.

Vaccibody is a new vaccine company providing a platform for both DNA-based and subunit vaccines. The high T-cell response seen in preclinical studies of Vaccibody vaccines makes this platform especially well suited for therapeutic cancer vaccines. Although young, the company is based on world-recognised expertise in Oslo and has already strong international collaborations with eg Southampton UK and CDC Atlanta. CEO Ole Henrik Brekke is looking for further opportunities.

Genetic Analysis is creating a great deal of excitement amongst both academic and industrial researchers with its GA-map™ technology, which enables profiling of gut microbiota. Changes in our gut bugs are increasingly being linked with a range of diseases and there is also growing evidence of their impact on neurological development. Genetic Analysis has already launched an infant microarray and CEO Morten Isaksen will be looking for collaboration partners.



Photo Bård Gudim, Forskningsrådet

siRNA sense is in the exciting field of RNA therapeutics.

siRNA sense has a research collaboration with PCI Biotech, financed by EU's Eurostars-programme, focusing on using PCI's light induced technology to enhance delivery of siRNA molecules to localised targets in the body.

For Nextera, CEO Hanne Mette Kristensen will be looking for to find collaboration partners who would license the platform for protein based drugs such as peptides, larger proteins and antibodies etc, and for siRNA sense, to find a biotech company in a suitable size and interest space for further collaboration on developing siRNA based drug candidates.

Although based in Lund, CRO **Stricent** has strong links with OCC because of its oncology expertise. In addition to consultancy, the company offers two powerful drug development tools - Abio-cess™, a development platform and Trial-on-Line™, an Electronic Data Capture system. Business Development Director Anna Thorsell is attending to advise on the advantages of doing biopharma and medtech development in the Nordic region.

In addition Susanne Werner and Anne-Brit Kolstø from Oslo Teknopol, together with Ole-Jørgen Marvik, Wilhem Wold and Knut Larsen from Innovation Norway will be available to answer general questions on Life Science opportunities in Oslo/Norway in general.

Photo Øyvind Heia



BMI have gathered a strong team of biomedical entrepreneurs.

Bio-Medisinsk Innovasjon (BMI) will be presenting two companies in their portfolio in particular - Nextera, a new antibody engineering company and siRNA sense, a siRNA-based drug development company.

Nextera builds on world leading Norwegian antibody expertise and promises next generation phage display. Its Taggerphage technology fosters easy display of two different proteins on the same phage particle, thus providing new functionality to existing phage display systems.



INVITATION

SCANDINAVIA PAVILION
WEDNESDAY MAY 5th
BIO 2010

May 5th, 2.30 p.m. Seminar:

"The Nordic Countries – the Goldmine of longitudinal -and register data" with speakers Nancy Pedersen, Karolinska Institutet and Kristian Hveem, HUNT Biobank

May 5th, 3.30 p.m. Reception:

We invite you to our popular yearly Scandinavian reception at BIO to network with our innovative companies and organizations. Come enjoy the company, the Carlsberg beer and live music by ABBA Salute.

Welcome!

SONITOR SENDS OUT STRONG SIGNALS IN US

Sonitor's ultrasound based hospital equipment tracking systems continue to make strong inroads in the US. Together with IBM and Agilsys they have installed a Real-Time Location Services system (RTLS) at St Michael's Medical Center, Newark, NJ

Saint Michael's Medical Center is using RTLS to automatically track equipment, alert staff when the required level of equipment is running low, and to ensure compliance with patient safety regulations. The new system will initially track more than 2,000 pieces of equipment across Saint Michael's. Ultrasound tags attached to equipment broadcast a unique identification signal to receivers without the risk of electromagnetic interference with other electronic patient care equipment. The ultrasound identification data is used by IBM's Real-Time Location Service software to not only track and visualize equipment with location accuracy to zone, room or sub-room levels, but to generate alerts and automate responses. For example, an alert can be generated when a heart monitor leaves an assigned area without authorization, or if a crash cart sits in the hallway too long.

"Saint Michael's is always under cost pressures, looking for ways to improve efficiency and focus more on the patient," said Angelo Schittone, vice president and chief information officer at Saint Michael's Medical Center. "We have highly skilled staff and caregivers. The new system allows our biomedical engineering team to better use their time managing and maintaining equipment and allows nurses to focus on patient care rather than looking for equipment."

AND GETS PERSONAL

Sonitor has also introduced a new Staff Tag. Developed in close cooperation with leading healthcare information technology providers and their hospital clients, the Staff Tag is small and lightweight and allows the facility's personal identification badge to be easily attached to provide an integrated badge system. The Staff Tag also features two buttons and a multi-colour LED that enables the wearer to communicate requests or status remotely, thus saving time and enhancing workflow. www.sonitor.com

TURNING HEALTHCARE WIRELESS

A Scandinavian Consortium of sensor developers, research institutions and companies has recently finalised the follow-on Biomedical Wireless Sensor network (BWSN 2) project (www.bwsn.net) funded by Nordic Innovations Centre and SNN.

Continuing the first project were from Sweden: Millicore, Novosense and Imego, from Norway Memscap, Novelda and the Interventional Centre at Oslo University Hospital and from Finland VTT. New project partners this time round were Delta from Denmark, and SINTEF from Norway. The BWSN projects have the same objective of linking all the various stages of patient treatment pathways - from home to hospital - through the use of wireless sensors. During BSWN2, a network of 7 wireless sensors has been implemented on a software platform from Imatis As. Preliminary clinical tests have been made in experimental and lab setting and the results can be seen on a video at <http://www.youtube.com/watch?v=hiHJTl7JMSE>. The project has aroused considerable interest internationally and Norway, which already has strong telemedicine traditions, is looking at further ways to secure leadership in this area through the Oslo Medtech Cluster and various Trondheim initiatives.



Sonitor's ultrasound tags can be detected anywhere in the hospital.



Oslo, September 15th - 17th, 2010

**Welcome to European Cancer Cluster Partnering
- The oncology event in Europe for biotechs, pharma, investors and academia.**



Oslo Cancer Cluster (Norway) and Cancer-Bio-Santé Cluster (Toulouse, France) welcomes you to our **oncology partnering event**, ECCP2010, which will take place in Oslo from September the 15th to 17th.

ECCP2010 is a business meeting aiming to build partnerships between emerging and established players in oncology, attract investments to innovative biotech companies and foster collaborations.



OSLO CANCER CLUSTER

has announced the initial programme for the second European Cancer Cluster Partnering meeting to be held in Oslo on 15 - 17 September.

According to OCC CEO Bjarte Reve, ECCP has been designed around eight compact sessions during the two-day conference: *“Oncology 2020”* is the theme for two opening sessions, which are followed by six core sessions addressing important aspects of oncology R&D, business development and investor relations with successful partnering as the overall aim.”


The keynote presentations on day one will address three topics to set the scene for the conference “Open innovation networks between academia and industry” will discuss new models for collaborating and driving innovation in cancer. “Oncology 2020 – perspectives in new drug development” will review emerging therapeutic approaches, new clinical perspectives and associated challenges. The session will be complemented by a talk dealing with “The Global Cancer Burden – an outlook for the next decade”. The day two “Oncology 2020 – Global networks to speed up innovation” session starts with a keynote on translating scientific concepts into innovative treatments – lessons learned and outlook for the next decade. Building on that, a roundtable will discuss how a “global bioscience gateway” involving partners from the US, Europe and China can accelerate the development of new cancer diagnostics and medicines.

The six core sessions will then focus on particular hot topics:

- I. Biomarkers – new companion diagnostics in oncology
- II. Clinical development in Oncology: how to be fast and cost-efficient
- III. Cancer-focused Clinical Trial Networks: accelerating R&D
- IV. How to make your company investable? How VCs look at your oncology assets
- V. Partnering: emerging strategies to tap innovation
- VI. Partnering strategies: positioning as key

“As well as returning delegates from last year in Toulouse, we have already received a great deal of interest from the “global” oncology community and expect to increase numbers from the US and Asia in particular this year. I look forward to welcoming them all to Oslo” concludes Reve.

For more information and to register visit www.eccp2010.com



Nansen was a polar explorer, humanitarian - and neuroscientist.

NANSEN NETWORK LAUNCH IN MAY

The Nansen Neuroscience Network, which aims to repeat the success of the Oslo Cancer Cluster and promote translational neuroscience in Norway and internationally, will officially launch on May 11, as a satellite meeting to the Department of Health Annual Health Conference at Oslo Plaza. Among the prominent speakers, will be the Norwegian Minister of health, the Rector of The University of Oslo, Ole Petter Ottersen, himself an internationally renowned neuroscientist, and the CEO of LMI, Karita Bekkemellem.

Also renowned as a polar explorer and humanitarian, Nansen was a professor of zoology and later oceanography at the University of Kristiania (now Oslo) and contributed with groundbreaking works in the fields of neurology and fluid dynamics. He was one of the founders of the neuron theory stating that the neural network consists of individual cells communicating with each other. He set out to study the nervous system of invertebrates and soon he became pre-occupied with the question of how nerve cells communicated with each other.

www.nansenneuro.com

VACCIBODY AS

COMPANY MISSION

The company's mission is to develop new effective vaccines against cancer and infectious diseases. The need for faster production turnaround time of more specific and effective drugs is driving the development of novel vaccines. Vaccibody AS aims to meet this demand through its proprietary vaccine platform.

TECHNOLOGY

The Vaccibody platform enables accurate targeting of vaccines to antigen-presenting cells. A Vaccibody vaccine comprises interchangeable modules for the design of a specific immune-response depending on the disease indication. It can be delivered as either a DNA vaccine or as protein subunit vaccine.

APPLICATIONS

The high T-cell response seen in preclinical studies of Vaccibody vaccines makes this platform especially well suited for therapeutic cancer vaccines. Vaccibody has shown superior effect in preclinical studies both for influenza, lymphoma and prostate cancer. The company has a broad range of collaborations with both industrial and academic partners.

MANAGEMENT

Ole Henrik Brekke, CEO,
Agnete Brunsvik Fredriksen, CSO

COLLABORATIONS

Centres for Disease Control, Atlanta, USA
University of Southampton, UK
University of Oslo, Norway
Oslo University Hospital, Norway
University of Bergen, Norway
National Veterinary Institute, Norway

INVESTORS

Bio-Medisinsk Innovasjon AS, Sarsia Seed AS, founders

WEBSITE

www.vaccibody.com



Photo Øyvind Heia

Oslo Teknopol

- your key to the Oslo region

Oslo Teknopol aims to stimulate innovation and attract foreign investments and talent to Norway's capital region. We offer free assistance and information about business conditions and opportunities within life sciences and other key knowledge-based clusters in the Oslo region:

- Maritime
- Energy and environmental technology
- Information and communication technology
- Life science
- Culture

Oslo Teknopol is a non-profit regional development agency, established by the City of Oslo and Akershus County Council.



Oslo Bio is a collaborative network of stakeholders from the life science cluster. Oslo Bio aims to strengthen the cluster and contribute to long term growth through marketing, initiating and facilitating development projects, and international collaboration. Oslo Teknopol act as the secretariat for Oslo Bio.

For more information contact:

Oslo Teknopol at info@oslo.teknopol.no

